BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is considered one of the Best Beaten Down Growth Stocks to Buy According to Analysts. On October 19, Sean Laaman from Morgan Stanley maintained a Buy rating on BMRN with a price target of $104. Laaman highlighted the company’s market position, growth potential, and promising pipeline, including BMN 351 and BMN 333. BioMarin Pharmaceutical Inc. is an international biopharmaceutical company focusing on rare genetic conditions.

Read more at Yahoo Finance: Morgan Stanley Maintains Buy on BioMarin Pharmaceutical (BMRN)